$ANIP
ANI Pharmaceuticals Inc Stock $anip

$anip Overview Financials Valuation SEC Filings Company Website

2015 Q2 Form 10-Q Financial Statement

#000114420415046165 Filed on August 04, 2015

Income Statement

Concept	2015 Q2	2014 Q4	2014 Q2
Revenue	$19.52M	$21.04M	$6.647M
YoY Change	193.61%	99.78%	8.05%
Cost Of Revenue	$3.141M	$3.670M	$2.117M
YoY Change	48.37%	26.12%	-2.49%
Gross Profit	$16.38M	$17.36M	$4.530M
YoY Change	261.48%	127.82%	13.79%
Gross Profit Margin	83.91%	82.52%	68.15%
Selling, General & Admin	$5.551M	$4.740M	$5.433M
YoY Change	2.17%	48.13%	-24.25%
% of Gross Profit	33.9%	27.3%	119.93%
Research & Development	$995.0K	$570.0K	$851.0K
YoY Change	16.92%	9.62%	94.74%
% of Gross Profit	6.08%	3.28%	18.79%
Depreciation & Amortization	$1.415M	$1.280M	$706.0K
YoY Change	100.42%	190.91%	380.27%
% of Gross Profit	8.64%	7.37%	15.58%
Operating Expenses	$6.546M	$6.600M	$6.284M
YoY Change	4.17%	58.65%	-17.41%
Operating Profit	$8.414M	$10.77M	-$2.460M
YoY Change	-442.03%	211.33%	-34.83%
Interest Expense	-$2.749M	-$800.0K	$3.000K
YoY Change	-91733.33%		-99.2%
% of Operating Profit	-32.67%	-7.43%
Other Income/Expense, Net	$0.00	$90.00K	-$39.00K
YoY Change	-100.0%	200.0%	-91.01%
Pretax Income	$5.665M	$10.06M	-$2.496M
YoY Change	-326.96%	188.25%	-45.54%
Income Tax	$2.094M	-$10.95M	-$133.0K
% Of Pretax Income	36.96%	-108.85%
Net Earnings	$3.571M	$21.01M	-$2.363M
YoY Change	-251.12%	512.54%	-48.44%
Net Earnings / Revenue	18.3%	99.87%	-35.55%
Basic Earnings Per Share	$0.31	$1.85	-$0.21
Diluted Earnings Per Share	$0.31	$1.82	-$0.21
COMMON SHARES
Basic Shares Outstanding	11.34M shares		11.23M shares
Diluted Shares Outstanding	11.55M shares		11.23M shares

Balance Sheet

Concept	2015 Q2	2014 Q4	2014 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$166.7M	$169.0M	$53.00M
YoY Change	214.53%	1422.52%	320.63%
Cash & Equivalents	$166.7M	$169.0M	$52.96M
Short-Term Investments
Other Short-Term Assets	$9.600M	$1.100M	$500.0K
YoY Change	1820.0%	83.33%	-80.77%
Inventory	$12.70M	$7.518M	$5.900M
Prepaid Expenses	$1.615M	$1.139M
Receivables	$18.88M	$17.30M	$7.800M
Other Receivables	$1.000M	$0.00	$0.00
Total Short-Term Assets	$208.9M	$195.0M	$67.20M
YoY Change	210.93%	603.53%	178.62%
LONG-TERM ASSETS
Property, Plant & Equipment	$5.249M	$5.223M	$4.600M
YoY Change	14.11%	15.12%	-2.97%
Goodwill	$1.838M	$1.838M
YoY Change		0.0%
Intangibles	$44.17M	$42.07M
YoY Change		304.14%
Long-Term Investments
YoY Change
Other Assets	$9.900M	$15.40M
YoY Change
Total Long-Term Assets	$61.17M	$68.72M	$28.20M
YoY Change	116.93%	309.43%	60.4%
TOTAL ASSETS
Total Short-Term Assets	$208.9M	$195.0M	$67.20M
Total Long-Term Assets	$61.17M	$68.72M	$28.20M
Total Assets	$270.1M	$263.7M	$95.40M
YoY Change	183.15%	492.6%	128.78%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.325M	$2.654M	$1.700M
YoY Change	-22.06%	85.72%	3.99%
Accrued Expenses	$3.900M	$1.269M	$1.100M
YoY Change	254.55%	-4.3%	5.83%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$6.949M	$13.23M	$3.800M
YoY Change	82.87%	274.02%	-38.34%
LONG-TERM LIABILITIES
Long-Term Debt	$113.7M	$106.5M	$0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$113.7M	$106.5M	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$6.949M	$13.23M	$3.800M
Total Long-Term Liabilities	$113.7M	$106.5M	$0.00
Total Liabilities	$120.6M	$119.8M	$3.800M
YoY Change	3074.24%	3285.33%	-38.71%
SHAREHOLDERS EQUITY
Retained Earnings	-$11.79M	-$19.73M
YoY Change		-59.31%
Common Stock	$1.000K	$1.000K
YoY Change		0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$113.0K	$0.00
YoY Change		-100.0%
Treasury Stock Shares	4.892K shares	0.000 shares	0.000 shares
Shareholders Equity	$149.5M	$139.8M	$91.60M
YoY Change
Total Liabilities & Shareholders Equity	$270.1M	$259.6M	$95.42M
YoY Change	183.08%	483.28%	129.06%

Cashflow Statement

Concept	2015 Q2	2014 Q4	2014 Q2
OPERATING ACTIVITIES
Net Income	$3.571M	$21.01M	-$2.363M
YoY Change	-251.12%	512.54%	-48.44%
Depreciation, Depletion And Amortization	$1.415M	$1.280M	$706.0K
YoY Change	100.42%	190.91%	380.27%
Cash From Operating Activities	$1.210M	$10.74M	$1.950M
YoY Change	-37.95%	-475.52%	-356.58%
INVESTING ACTIVITIES
Capital Expenditures	$4.300M	-$340.0K	-$250.0K
YoY Change	-1820.0%	1033.33%	1150.0%
Acquisitions
YoY Change
Other Investing Activities	-$4.500M	$0.00	$0.00
YoY Change		-100.0%	-100.0%
Cash From Investing Activities	-$200.0K	-$330.0K	-$250.0K
YoY Change	-20.0%	-114.8%	-101.38%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	160.0K	123.6M	-110.0K
YoY Change	-245.45%	15156.79%	-97.74%
NET CHANGE
Cash From Operating Activities	1.210M	10.74M	1.950M
Cash From Investing Activities	-200.0K	-330.0K	-250.0K
Cash From Financing Activities	160.0K	123.6M	-110.0K
Net Change In Cash	1.170M	134.0M	1.590M
YoY Change	-26.42%	74338.89%	-87.33%
FREE CASH FLOW
Cash From Operating Activities	$1.210M	$10.74M	$1.950M
Capital Expenditures	$4.300M	-$340.0K	-$250.0K
Free Cash Flow	-$3.090M	$11.08M	$2.200M
YoY Change	-240.45%	-491.52%	-397.3%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	us-gaap	Nature Of Operations NatureOfOperations	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"><b>Overview</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"><b> </b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px 0px 0px 0.25in; FONT: 10pt Times New Roman, Times, Serif">ANI Pharmaceuticals, Inc. and its subsidiary, ANIP Acquisition Company (together, “ANI,” the “Company,” “we,” “us,” or “our”) is an integrated specialty pharmaceutical company developing, manufacturing, and marketing branded and generic prescription pharmaceuticals. Our targeted areas of product development currently include narcotics, oncolytics (anti-cancers), hormones and steroids, and complex formulations involving extended release and combination products. We have two pharmaceutical manufacturing facilities located in Baudette, Minnesota that are capable of producing oral solid dose products, as well as liquids and topicals, narcotics, and potent products that must be manufactured in a fully-contained environment. Our strategy is to use our assets to develop, acquire, manufacture, and market branded and generic specialty prescription pharmaceuticals. By executing this strategy, we believe we will be able to continue to grow the business, expand and diversify our product portfolio, and create long-term value for our investors.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2014Q4	us-gaap	Deferred Tax Assets Net Noncurrent DeferredTaxAssetsNetNoncurrent	7796000	USD
CY2015Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	44174000	USD
CY2015Q2	us-gaap	Deferred Tax Assets Net Noncurrent DeferredTaxAssetsNetNoncurrent	7027000	USD
CY2014Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	42067000	USD
CY2015Q2	us-gaap	Goodwill Goodwill	1838000	USD
CY2014Q4	us-gaap	Goodwill Goodwill	1838000	USD
CY2014Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2654000	USD
CY2015Q2	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	1615000	USD
CY2015Q2	us-gaap	Prepaid Taxes PrepaidTaxes	1022000	USD
CY2014Q4	us-gaap	Prepaid Taxes PrepaidTaxes	0	USD
CY2014Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	1983000	USD
CY2015Q2	us-gaap	Assets Current AssetsCurrent	208948000	USD
CY2014Q4	us-gaap	Assets Current AssetsCurrent	203478000	USD
CY2015Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5249000	USD
CY2014Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5223000	USD
CY2015Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	844000	USD
CY2014Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1348000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1227000	USD
CY2015Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	5551000	USD
CY2014Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	5433000	USD
	us-gaap	Use Of Estimates UseOfEstimates	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px 0px 0px 0.25in; FONT: 10pt Times New Roman, Times, Serif"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px 0px 0px 0.25in; FONT: 10pt Times New Roman, Times, Serif"> <b>Use of Estimates</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px 0px 0px 0.25in; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px 0px 0px 0.25in; FONT: 10pt Times New Roman, Times, Serif"> The preparation of financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reporting period. In the accompanying unaudited interim condensed consolidated financial statements, estimates are used for, but not limited to, stock-based compensation, allowance for doubtful accounts, accruals for chargebacks, rebates, returns and other allowances, allowance for inventory obsolescence, allowances for contingencies and litigation, fair value of long-lived assets, income tax provision, deferred taxes and valuation allowance, and the depreciable and amortizable lives of long-lived assets. Actual results could differ from those estimates.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2015Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	166731000	USD
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	169037000	USD
CY2015Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	18880000	USD
CY2014Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	17297000	USD
CY2015Q2	us-gaap	Inventory Net InventoryNet	12701000	USD
CY2014Q4	us-gaap	Inventory Net InventoryNet	7518000	USD
CY2015Q2	us-gaap	Deferred Tax Assets Net Current DeferredTaxAssetsNetCurrent	7999000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Net Current DeferredTaxAssetsNetCurrent	7643000	USD
CY2014Q4	anip	Class C Special Stock Value ClassCSpecialStockValue	0	USD
CY2015Q2	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2014Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2015Q2	us-gaap	Treasury Stock Value TreasuryStockValue	113000	USD
CY2014Q4	us-gaap	Treasury Stock Value TreasuryStockValue	0	USD
CY2015Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	161397000	USD
CY2014Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	159509000	USD
CY2015Q2	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	2885000	USD
CY2014Q4	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	3307000	USD
CY2015Q2	us-gaap	Assets Assets	270121000	USD
CY2014Q4	us-gaap	Assets Assets	263709000	USD
CY2015Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	1325000	USD
CY2015Q2	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	0	USD
CY2014Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	4253000	USD
CY2015Q2	anip	Accrued Medicaid Rebates AccruedMedicaidRebates	1891000	USD
CY2014Q4	anip	Accrued Medicaid Rebates AccruedMedicaidRebates	2264000	USD
CY2015Q2	anip	Returned Goods Reserve ReturnedGoodsReserve	1719000	USD
CY2014Q4	anip	Returned Goods Reserve ReturnedGoodsReserve	1445000	USD
CY2015Q2	us-gaap	Liabilities Current LiabilitiesCurrent	6949000	USD
CY2014Q4	us-gaap	Liabilities Current LiabilitiesCurrent	13233000	USD
CY2015Q2	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	113672000	USD
CY2014Q4	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	110691000	USD
CY2015Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2014Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2015Q2	us-gaap	Common Stock Value CommonStockValue	1000	USD
CY2014Q4	us-gaap	Common Stock Value CommonStockValue	1000	USD
CY2015Q2	anip	Class C Special Stock Value ClassCSpecialStockValue	0	USD
CY2015Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-11785000	USD
CY2014Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-19725000	USD
CY2015Q2	us-gaap	Stockholders Equity StockholdersEquity	149500000	USD
CY2014Q4	us-gaap	Stockholders Equity StockholdersEquity	139785000	USD
CY2015Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	270121000	USD
CY2015Q2	us-gaap	Cost Of Revenue CostOfRevenue	3141000	USD
CY2014Q2	us-gaap	Cost Of Revenue CostOfRevenue	2117000	USD
	us-gaap	Cost Of Revenue CostOfRevenue	5892000	USD
	us-gaap	Cost Of Revenue CostOfRevenue	4739000	USD
CY2015Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	995000	USD
CY2014Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	851000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1398000	USD
CY2014Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	263709000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	10302000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	9136000	USD
CY2015Q2	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1415000	USD
CY2014Q2	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	706000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2742000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1409000	USD
CY2015Q2	us-gaap	Costs And Expenses CostsAndExpenses	11102000	USD
CY2015Q2	us-gaap	Liabilities Liabilities	120621000	USD
CY2014Q4	us-gaap	Liabilities Liabilities	123924000	USD
CY2015Q2	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	0	USD
CY2014Q4	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	0	USD
CY2015Q2	us-gaap	Revenues Revenues	19516000	USD
CY2014Q2	us-gaap	Revenues Revenues	6647000	USD
	us-gaap	Revenues Revenues	38315000	USD
	us-gaap	Revenues Revenues	17546000	USD
CY2014Q2	us-gaap	Costs And Expenses CostsAndExpenses	9107000	USD
	us-gaap	Costs And Expenses CostsAndExpenses	20334000	USD
	us-gaap	Costs And Expenses CostsAndExpenses	16511000	USD
CY2015Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	8414000	USD
CY2014Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-2460000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	17981000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	1035000	USD
CY2015Q2	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-2749000	USD
CY2014Q2	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	3000	USD
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-5474000	USD
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	3000	USD
CY2015Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	0	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	68000	USD
CY2015Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2094000	USD
CY2014Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-133000	USD
CY2014Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-39000	USD
CY2015Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	5665000	USD
CY2015Q2	us-gaap	Net Income Loss NetIncomeLoss	3571000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-10000	USD
CY2014Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2496000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	12575000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	1028000	USD
CY2014Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.21
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.68
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.09
CY2015Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	11344000	shares
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	4635000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	32000	USD
CY2014Q2	us-gaap	Net Income Loss NetIncomeLoss	-2363000	USD
	us-gaap	Net Income Loss NetIncomeLoss	7940000	USD
	us-gaap	Net Income Loss NetIncomeLoss	996000	USD
CY2015Q2	us-gaap	Notes Payable Fair Value Disclosure NotesPayableFairValueDisclosure	163700000	USD
	us-gaap	Fair Value Inputs Discount Rate FairValueInputsDiscountRate	0.15	pure
CY2015Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.31
CY2014Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.21
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.70
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.09
CY2015Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.31
CY2014Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	11233000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	11335000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	10612000	shares
CY2015Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	11549000	shares
CY2014Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	11233000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	11556000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	10640000	shares
CY2015Q1	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	4500000	USD
CY2015Q2	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	1078000	USD
	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	2156000	USD
CY2015Q2	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	1501000	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	2981000	USD
CY2015Q2	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	211000	USD
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	422000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	1597000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	2026000	USD
CY2015Q2	us-gaap	Interest Costs Capitalized Adjustment InterestCostsCapitalizedAdjustment	6000	USD
	us-gaap	Interest Costs Capitalized Adjustment InterestCostsCapitalizedAdjustment	15000	USD
	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	413000	USD
	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	0	USD
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-3388000	USD
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	0	USD
CY2015Q2	us-gaap	Interest Expense Debt InterestExpenseDebt	2784000	USD
	us-gaap	Interest Expense Debt InterestExpenseDebt	5544000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1583000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-4719000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	5183000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	2394000	USD
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-368000	USD
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-87000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1379000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	302000	USD
	anip	Increase Decrease In Accrued Compensation Liabilities IncreaseDecreaseInAccruedCompensationLiabilities	-504000	USD
	anip	Increase Decrease In Accrued Compensation Liabilities IncreaseDecreaseInAccruedCompensationLiabilities	-81000	USD
	us-gaap	Increase Decrease In Income Taxes IncreaseDecreaseInIncomeTaxes	-5275000	USD
	us-gaap	Increase Decrease In Income Taxes IncreaseDecreaseInIncomeTaxes	3000	USD
	anip	Increase Decrease Accrued Medicaid Rebates IncreaseDecreaseAccruedMedicaidRebates	-373000	USD
	anip	Increase Decrease Accrued Medicaid Rebates IncreaseDecreaseAccruedMedicaidRebates	-56000	USD
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	175000	USD
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	122000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	2326000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	7133000	USD
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	4500000	USD
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	12517000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	310000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	371000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-4810000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-12888000	USD
	us-gaap	Proceeds From Repurchase Of Equity ProceedsFromRepurchaseOfEquity	0	USD
	us-gaap	Proceeds From Repurchase Of Equity ProceedsFromRepurchaseOfEquity	46680000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	244000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	743000	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	180000	USD
	us-gaap	Excess Tax Benefit From Share Based Compensation Financing Activities ExcessTaxBenefitFromShareBasedCompensationFinancingActivities	47000	USD
	us-gaap	Excess Tax Benefit From Share Based Compensation Financing Activities ExcessTaxBenefitFromShareBasedCompensationFinancingActivities	8000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	178000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	47611000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-2306000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	41856000	USD
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	11105000	USD
CY2014Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	52961000	USD
	us-gaap	Interest Paid InterestPaid	2048000	USD
	us-gaap	Interest Paid InterestPaid	-3000	USD
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	9450000	USD
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	60000	USD
	us-gaap	Noncash Or Part Noncash Acquisition Fixed Assets Acquired1 NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1	50000	USD
	us-gaap	Noncash Or Part Noncash Acquisition Fixed Assets Acquired1 NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1	0	USD
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	113000	USD
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	0	USD
CY2015Q2	us-gaap	Valuation Allowances And Reserves Balance ValuationAllowancesAndReservesBalance	7724000	USD
CY2014Q4	us-gaap	Valuation Allowances And Reserves Balance ValuationAllowancesAndReservesBalance	8708000	USD
CY2015Q2	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	200000	USD
CY2015Q2	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	20000	USD
CY2014Q2	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	19000	USD
	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	38000	USD
	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	36000	USD
CY2015Q2	us-gaap	Treasury Stock Shares TreasuryStockShares	4892	shares
CY2014Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	0	shares
CY2015Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2014Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2015Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1666667	shares
CY2014Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1666667	shares
CY2015Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2014Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2015Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2014Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2015Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	100000	USD
CY2015Q2	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.370	pure
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.369	pure
CY2014Q2	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.053	pure
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.029	pure
	anip	Class Of Warrant Or Right Number Of Securities Called By Warrants That Expired During Period Number ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsThatExpiredDuringPeriodNumber	100000	shares
CY2015Q2	anip	Class Of Warrant Or Right Number Of Securities Called By Warrants That Expired During Period Number ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsThatExpiredDuringPeriodNumber	100000	shares
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	600000	shares
CY2015Q2	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	800000	USD
	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	1300000	USD
CY2014Q1	anip	Stock Issued During Period Due To Warrant Exercise Number StockIssuedDuringPeriodDueToWarrantExerciseNumber	20000	shares
CY2014Q2	anip	Class Of Warrant Or Right Number Of Securities Called By Warrants That Expired During Period Number ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsThatExpiredDuringPeriodNumber	0	shares
	anip	Class Of Warrant Or Right Number Of Securities Called By Warrants That Expired During Period Number ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsThatExpiredDuringPeriodNumber	0	shares
CY2014Q2	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	1900000	USD
	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	1900000	USD
CY2015Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	3547000	USD
CY2014Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-2363000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	7887000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	985000	USD
CY2015Q2	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-3548000	USD
CY2014Q2	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	2363000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-7888000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-985000	USD
CY2015Q2	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	205000	shares
CY2014Q2	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0	shares
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	221000	shares
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	28000	shares
CY2015Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4600000	shares
CY2014Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1100000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4600000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	700000	shares
CY2015Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	2400000	shares
CY2014Q2	us-gaap	Depreciation Depreciation	100000	USD
CY2015Q2	us-gaap	Inventory Raw Materials InventoryRawMaterials	9945000	USD
CY2014Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	5056000	USD
CY2015Q2	us-gaap	Retail Related Inventory Packaging And Other Supplies RetailRelatedInventoryPackagingAndOtherSupplies	922000	USD
CY2014Q4	us-gaap	Retail Related Inventory Packaging And Other Supplies RetailRelatedInventoryPackagingAndOtherSupplies	794000	USD
CY2015Q2	us-gaap	Inventory Work In Process InventoryWorkInProcess	350000	USD
CY2014Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	411000	USD
CY2015Q2	us-gaap	Inventory Finished Goods InventoryFinishedGoods	1763000	USD
CY2014Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	1368000	USD
CY2015Q2	us-gaap	Inventory Gross InventoryGross	12980000	USD
CY2014Q4	us-gaap	Inventory Gross InventoryGross	7629000	USD
CY2015Q2	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	279000	USD
CY2014Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	111000	USD
CY2015Q2	us-gaap	Depreciation Depreciation	200000	USD
CY2015Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	9392000	USD
CY2014Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	9017000	USD
CY2015Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	4143000	USD
CY2014Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3794000	USD
CY2015Q2	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	50499000	USD
CY2014Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	45999000	USD
CY2015Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	6325000	USD
CY2014Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	3932000	USD
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2015Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	2467000	USD
CY2015Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	4935000	USD
CY2015Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	4935000	USD
CY2015Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	4935000	USD
CY2015Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	4935000	USD
CY2015Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	21967000	USD
CY2015Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	44174000	USD
CY2015Q2	us-gaap	Goodwill Gross GoodwillGross	1800000	USD
CY2015Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1200000	USD
CY2014Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	600000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	2400000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1100000	USD
	dei	Document Type DocumentType	10-Q
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Period End Date DocumentPeriodEndDate	2015-06-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2015
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Entity Registrant Name EntityRegistrantName	ANI PHARMACEUTICALS INC
	dei	Entity Central Index Key EntityCentralIndexKey	0001023024
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
	dei	Trading Symbol TradingSymbol	ANIP
CY2014Q2	anip	Share Based Compensation Catch Up ShareBasedCompensationCatchUp	1300000	USD
	anip	Share Based Compensation Catch Up ShareBasedCompensationCatchUp	1300000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	100000	USD
CY2015Q2	us-gaap	Interest Costs Capitalized InterestCostsCapitalized	6000	USD
	us-gaap	Interest Costs Capitalized InterestCostsCapitalized	15000	USD
CY2015Q2	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	3571000	USD
CY2014Q2	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-2363000	USD
	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	7940000	USD
	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	996000	USD
	us-gaap	Depreciation Depreciation	300000	USD
	us-gaap	Depreciation Depreciation	300000	USD

Files In Submission

Name	View Source	Status
0001144204-15-046165-index-headers.html	Edgar Link	pending
0001144204-15-046165-index.html	Edgar Link	pending
0001144204-15-046165.txt	Edgar Link	pending
0001144204-15-046165-xbrl.zip	Edgar Link	pending
anip-20150630.xml	Edgar Link	completed
anip-20150630.xsd	Edgar Link	pending
anip-20150630_cal.xml	Edgar Link	unprocessable
anip-20150630_def.xml	Edgar Link	unprocessable
anip-20150630_lab.xml	Edgar Link	unprocessable
anip-20150630_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
v415947_10q.htm	Edgar Link	pending
v415947_ex31-1.htm	Edgar Link	pending
v415947_ex31-2.htm	Edgar Link	pending
v415947_ex32-1.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ANIP
ANI Pharmaceuticals Inc Stock $anip

2015 Q2 Form 10-Q Financial Statement

#000114420415046165 Filed on August 04, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ANIP ANI Pharmaceuticals Inc Stock $anip

2015 Q2 Form 10-Q Financial Statement

#000114420415046165 Filed on August 04, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ANIP
ANI Pharmaceuticals Inc Stock $anip